Phathom Pharmaceuticals (PHAT) Cash & Equivalents (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Cash & Equivalents data on file, last reported at $183.8 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 14.6% year-over-year to $183.8 million in Q1 2026; TTM through Mar 2026 was $183.8 million, a 14.6% decrease from a year earlier, with the FY2025 full-year figure at $132.8 million, down 55.74% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $183.8 million, up from $132.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for PHAT reached as high as $384.3 million in Q4 2023 and fell as low as $130.1 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $220.1 million across 5 years, with a median of $207.9 million in 2022.
• Across the five-year window, Cash & Equivalents jumped 149.92% in 2024 and slumped 59.11% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $155.9 million in 2022, then soared by 146.49% to $384.3 million in 2023, then dropped by 21.89% to $300.1 million in 2024, then sank by 55.74% to $132.8 million in 2025, then surged by 38.34% to $183.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $183.8 million in Q1 2026, $132.8 million in Q4 2025, and $138.0 million in Q3 2025.